A New Era in Oncology

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving survival outcomes for patients with cancer. We use our proprietary ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.

Our highly experienced management team has a successful track record of building global, integrated biopharmaceutical companies and bringing life-saving oncology therapeutics to patients.

Host a BIG PINK Party This October

National Breast Cancer Awareness Month

Our Values

MISSION: To Transform Chemotherapy and Pioneer a New Era in Oncology

"Utilising our proprietary ProTide technology platform we are developing new medicines designed to overcome key cancer resistance mechanisms and improve the survival outcomes for patients."

Hugh S. Griffith

Founder & CEO
Hugh Griffith


Our lead product candidate is designed to overcome the key cancer resistance mechanisms associated with gemcitabine. Currently in Phase I, II and III studies.


Our second ProTide is designed to overcome the key cancer resistance mechanisms associated with 5-FU. Currently in a Phase I study in patients with advanced solid tumours.


A ProTide transformation of cordycepin, a novel nucleoside analog with a unique mode of action and potent anti-cancer activity in preclinical studies. Initiating a Phase I study in 2018.


NuCana's ProTide technology is a powerful platform generating new anti-cancer medicines designed to overcome the key cancer resistance mechanisms.


We take a scientifically driven approach to designing our ProTides to address some of the most significant unmet medical needs in oncology.


NuCana Reports Additional Promising Clinical Data on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer at ESMO 2018.

NCRI logo

National Cancer Research Institute Conference 2018

Scottish Event Campus, Glasgow, UK
4-6 November 2018

NuCana logo

NuCana are proud to be supporting the educational session, “Advances in Pancreatic and Biliary Tract Cancers” at 2018 NCRI Cancer Conference, Glasgow, UK.


Meet Our Executive Team

Hugh Griffith

Hugh Griffith

Chief Executive Officer

Christopher Wood

Christopher Wood

Chief Medical Officer

San Francisco

Don Munoz

Chief Financial Officer

Global Headquarters

3 Lochside Way
EH12 9DT
United Kingdom

Telephone: +44 (0)131 357 1111

E-mail: info@nucana.com

U.S. Office

275 Grove Street
Newton, MA 02466

Telephone: +1 617 663 4821


Contact us